Table 1 Study objectives for COMPEL

Primary Objective

To assess mean change from baseline in the frequency of headache days per 28-day period at 108 weeks (following 9 treatments) using a patient diary completed via IVRS.

Secondary Objectives

To assess mean change from baseline in the frequency of headache days for the 28-day period ending at 60 weeks (following 5 treatments).

To assess the efficacy of onabotulinumtoxinA treatment for CM in adult patients as measured by the mean change from baseline in total HIT-6 score over a 4-week period at 108 weeks (following 9 treatments) and at 60 weeks (following 5 treatments).

To evaluate the long-term safety and tolerability (9 treatment cycles) of onabotulinumtoxinA for CM in adult patients.